Germline AluScan-CNV is a breakthrough platform technology for effective first-line prediction of complex diseases such as cancers and psychiatric disorders based on germline genome copy number variation profiles Prediction of disease risk well before disease onset, providing opportunity for effective prevention. Demonstrated effectiveness in predicting brain metastasis from lung cancers enables proactive clinical management of such a most devastating complication Cost-effective in both sample requirement and test expenditure. No need for tissue biopsy. Only less than one tenth of mini-grams of white blood cell DNA is required, a thirty-fold deduction than conventional methods Artificial intelligence analysis of data generated by AluScan may achieve greatly improved sensitivity at much reduced cost of calculation power and energy, due to extra high signal-to-noise ratio